Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,636
datasets available to search
ShareScore release 0.9.0
Dataset results
1,636 results for “Head and neck cancer;”
Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery
ClinicalTrials.gov study NCT00003576. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer
ClinicalTrials.gov study NCT00248235. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Exploratory Study of Early Biomarkers Allowing Dynamic Assessment of Response to Treatment in Cancers of the Head and Neck
ClinicalTrials.gov study NCT05644457. IPD Sharing: NO. Countries: 1. Publications: 11.
Leg Function and ADL After ALT Reconstruction for Head and Neck Cancer
ClinicalTrials.gov study NCT02332161. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: can disease-specific utilities be obtained?
<p class="Default"><b>Introduction</b></p> <p class="Default">Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is available. The objective of this study is to develop a mapping function translating the EORTC QLQ-C30 to EQ-5D-derived utilities for HNC through regression modeling, and to explore the added value of disease-specific EORTC QLQ-H&N35 scales to the model.</p> <p class="Default"> </p> <p class="Default"><b>Methods</b></p> <p class="Default">Data was obtained on patients with primary HNC treated with curative intent derived from two hospitals. Model development was conducted in two phases: 1. Predictor selection based on theory- and data-driven methods, resulting in three sets of potential predictors from the quality of life questionnaires; 2. Selection of the best out of four methods: ordinary-least squares, mixed-effects linear, Cox and beta regression, using the first set of predictors from EORTC QLQ-C30 scales with most correspondence to EQ-5D dimensions. Using a stepwise approach, we assessed added values of predictors in the other two sets. Model fit was assessed using Akaike and Bayesian Information Criterion (AIC and BIC) and model performance was evaluated by MAE, RMSE and limits of agreement (LOA).</p> <p class="Default"> </p> <p class="Default"><b>Results </b></p> <p class="Default">The beta regression model showed best model fit, with global health status, physical-, role- and emotional functioning and pain scales as predictors. Adding HNC-specific scales did not improve the model. Model performance was reasonable; R<sup>2</sup>=0.39, MAE=0.0949, RMSE=0.1209, 95% LOA of -0.243 to 0.231 (bias -0.01), with an error correlation of 0.32. The estimated shrinkage factor was 0.90.</p> <p class="Default"> </p> <p class="Default"><b>Conclusions</b></p> <p>Selected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients.</p>
Compendium of primary head and neck cancer gene expression datasets with accompanying clinical data
<p>We assembled a compendium of 30 primary HNC gene expression datasets with accompanying clinical data, representing the largest such resource for HNC. This resource was specifically built to identify genes associated with two outcome variables: patient survival and lymph node metastasis (LNM) status. Meta-analyses were applied to uniformly preprocessed gene expression data, as in our PRECOG resource (Gentles et al, Nat Med, 2016). Briefly, datasets were quality controlled, normalized, log transformed, and standardized to calculate gene expression profiles. Clinical data were manually curated and included survival and LNM status as well as variables relevant to HNC prognosis, such as tumor grade, tumor subanatomic location, and HPV status. The resulting 30 cleaned studies included 2,134 HNC tumors. 1,666 patients (across 17 cohorts) had survival outcome data and 1,490 patients (21 cohorts) had LNM status. Fully processed datasets are provided here as a resource to enable efficient meta-analyses of gene expression data in head and neck cancer.</p>
Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers
ClinicalTrials.gov study NCT07072325. IPD Sharing: NO. Countries: 0. Publications: 13.
UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
ClinicalTrials.gov study NCT00570232. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Acupoint Stimulation for Pain Reduction and the Associated Benefits in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy
ClinicalTrials.gov study NCT03640195. IPD Sharing: NO. Countries: 0. Publications: 1.
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
ClinicalTrials.gov study NCT01044433. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study for Patients With Head and Neck Cancer
ClinicalTrials.gov study NCT00415194. IPD Sharing: Not stated. Countries: 21. Publications: 0.
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
ClinicalTrials.gov study NCT04144517. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
ClinicalTrials.gov study NCT01711541. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301
ClinicalTrials.gov study NCT01487733. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
ClinicalTrials.gov study NCT00468169. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
ClinicalTrials.gov study NCT02331134. IPD Sharing: NO. Countries: 1. Publications: 0.
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
ClinicalTrials.gov study NCT04217057. IPD Sharing: NO. Countries: 1. Publications: 0.
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
ClinicalTrials.gov study NCT02841748. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Optimized Intensity Modulated Irradiation for Head and Neck Cancer
ClinicalTrials.gov study NCT00580983. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Low-Cost, Portable Flexible Nasopharyngoscope in Head & Neck Cancers in Low Resource Settings - Optimization Phase
ClinicalTrials.gov study NCT04905134. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.